Tags:BioTechDevelopmentDrugGrowthMarketMedTechPlatformProductTechnology
Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy). Our platform is commercially validated by well over $1.0 billion in technology out-licensing deals with partners including ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio and Kyowa Kirin. These partnerships have rapidly translated Synaffix technology into 11 ADCs currently in development by our partners, where 3 of these are already available in Phase 1 clinical trials. Through the platform, we can rapidly generate best-in-class ADCs for our partners from any antibody and our patent portfolio protects our proprietary processes and any resulting Products through at least 2039. Additionally, Synaffix technology is being deployed to address unmet medical need in several multi-billion-dollar, high growth market segments such as immune cell engagers and targeted gene therapy.
Location: Netherlands, North Holland, Amsterdam
Member count: 11-50
Founded date: 2010

Investors 2

Mentions in press and media 4

DateTitleDescriptionCategoryAuthorSource
06.02.2023Chong Kun ...Synaffix to provide access to ...--einpresswi...
04.01.2023Hummingbir...Synaffix to provide Hummingbir...--en.prnasia...
29.06.2021Innovent B...SAN FRANCISCO and SUZHOU, Chin...--marketscre...
29.06.2021Innovent A...SAN FRANCISCO and SUZHOU, Chin...--en.prnasia...